Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
University of Texas |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00238186 |
RATIONALE: Biological therapies, such as denileukin diftitox, may be able to carry tumor-killing substances directly to tumor cells.
PURPOSE: This phase II trial is studying how well denileukin diftitox works in treating patients with stage III or stage IV ovarian epithelial or primary peritoneal cancer.
Condition | Intervention | Phase |
---|---|---|
Ovarian Cancer Peritoneal Cavity Cancer |
Biological: denileukin diftitox |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized |
Official Title: | A Phase II Trial of Intravenous Ontak to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, or Extraovarian Peritoneal Carcinoma, Failing or Ineligible for First-Line Therapy |
Estimated Enrollment: | 60 |
Study Start Date: | December 2005 |
Estimated Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a non-randomized, multicenter study.
Patients receive denileukin diftitox IV over 1 hour once in week 1. Courses repeat monthly in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond achieving a documented response.
After completion of study treatment, patients are followed at 6 weeks, 3 months, and then every 3 months thereafter.
PROJECTED ACCRUAL: A total of 20-60 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed* ovarian epithelial or primary peritoneal cancer
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Immunologic
No history of autoimmune disease, including any of the following conditions:
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
United States, Texas | |
University of Texas Health Science Center at San Antonio | Recruiting |
San Antonio, Texas, United States, 78229-3900 | |
Contact: Tyler Curiel, MD, MPH 210-567-4777 curielt@uthscsa.edu |
Study Chair: | Tyler Curiel, MD, MPH | University of Texas |
Investigator: | Pui C. Cheng, MD | Tulane University Health Sciences Center |
Investigator: | Danny R. Barnhill, MD | Stanley S. Scott Cancer Center at Louisiana State University Medical Center - New Orleans |
Responsible Party: | University of Texas Health Science Center at San Antonio ( Tyler Curiel ) |
Study ID Numbers: | CDR0000445063, UTHSC-HSC20070042H, TULCC-TC-01-4, TULCC-C0307 |
Study First Received: | October 12, 2005 |
Last Updated: | July 7, 2009 |
ClinicalTrials.gov Identifier: | NCT00238186 History of Changes |
Health Authority: | Unspecified |
recurrent ovarian epithelial cancer stage III ovarian epithelial cancer stage IV ovarian epithelial cancer peritoneal cavity cancer |
Digestive System Neoplasms Ovarian Neoplasms Gonadal Disorders Genital Neoplasms, Female Endocrine System Diseases Urogenital Neoplasms Ovarian Diseases Ovarian Epithelial Cancer Abdominal Neoplasms Recurrence Carcinoma Genital Diseases, Female |
Digestive System Diseases Analgesics, Non-Narcotic Interleukin-2 Denileukin diftitox Peritoneal Diseases Ovarian Cancer Gastrointestinal Neoplasms Peripheral Nervous System Agents Analgesics Endocrinopathy Peritoneal Neoplasms Endocrine Gland Neoplasms |
Gonadal Disorders Antineoplastic Agents Physiological Effects of Drugs Urogenital Neoplasms Ovarian Diseases Genital Diseases, Female Neoplasms by Site Sensory System Agents Therapeutic Uses Peritoneal Diseases Analgesics Endocrine Gland Neoplasms Ovarian Neoplasms Digestive System Neoplasms |
Genital Neoplasms, Female Endocrine System Diseases Abdominal Neoplasms Pharmacologic Actions Adnexal Diseases Neoplasms Digestive System Diseases Interleukin-2 Analgesics, Non-Narcotic Denileukin diftitox Peritoneal Neoplasms Peripheral Nervous System Agents Central Nervous System Agents |